Portfolio & Technology

Portfolio overview

BioXmark® is a liquid fiducial marker for human use to mark soft tissue for enhanced visibility on medical imaging.
PetXmark™ is a liquid fiducial marker for use to radiographically mark subcutaneous tissue in dogs and cats and our first veterinary product on the market in the United States.

Technology platform and Intellectual Property

Nanovi builds on a patent-protected technology platform that is co-invented and co-owned with the Technical University of Denmark – DTU. Thomas L. Andresen, professor at DTU Health Tech, Nanovi founder and board member, is the main inventor of the technology.

The platform consists of carbohydrate based biomaterial compositions to design and synthesize liquid gels for medical applications, bridging advanced diagnostic imaging techniques and therapeutic inventions. The gels allow for simple non-invasive injection, multimodality visualization and guidance of radiation therapy and surgical procedures.

Under a framework license and option agreement with DTU, Nanovi has global development and commercial rights to the platform and a first-right of refusal to related medical device inventions for use in the fields of radiotherapy and surgery.

Nanovi has co-ownership and global commercial rights to a patent-protected biomaterial technology platform for medical device inventions in the fields of radiotherapy and surgery.

Nanovi has a portfolio of 6 international families of issued patents and patent applications co-owned with DTU – The Technical University of Denmark). These patent families constitute a strong protection of the company’s technology and product rights.

Overview of Nanovi patents


Gel formulations for guiding radio therapy


Gel formulations for local drug release


Palpaple marker composition


Development of injectable fiducial marker for image guided radiotherapy with dual MRI and CT visibility


Multimodal fiducial markers for surgical guidance (NIR)


Brachygel treatment of cancer or for guidance of surgery